Rocio Alejandra Seniuk

Ms. Rocio Alejandra Seniuk

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
ATAyelén Toro
Ayelén Toro
MRMaria Sol Ruiz
Maria Sol Ruiz
SLSofia Lage-Vickers
Sofia Lage-Vickers
PSPablo Sanchis
Pablo Sanchis
Agustina Ayelen SabaterAgustina Ayelen Sabater
Agustina Ayelen Sabater
GGGeraldine Gueron
Geraldine Gueron
Heme oxygenase 1 (HO-1), the rate-limiting enzyme in heme degradation, is involved in the maintenance of cellular homeostasis, exerting a cytoprotective role by its antioxidative and anti-inflammatory functions. HO-1 and its end products, biliverdin, carbon monoxide and free iron (Fe2+), confer cytoprotection against inflammatory and oxidative injury. Additionally, HO-1 exerts antiviral properties against a diverse range of viral infections by interfering with replication or activating the interferon (IFN) pathway. Severe cases of coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are characterized by systemic hyperinflammation, which, in some cases, leads to severe or fatal symptoms as a consequence of respiratory failure, lung and heart damage, kidney failure, and nervous system complications. This review summarizes the current research on the protective role of HO-1 in inflammatory diseases and against a wide range of viral infections, positioning HO-1 as an attractive target to ameliorate clinical manifestations during COVID-19.

30 September 2022 in Viruses
Verified
Journal Article
Open access
PDF file
ATAyelén Toro
Ayelén Toro
SLSofia Lage-Vickers
Sofia Lage-Vickers
Juan BizzottoJuan Bizzotto
Juan Bizzotto
FVFelipe Vilicich
Felipe Vilicich
Agustina Ayelen SabaterAgustina Ayelen Sabater
Agustina Ayelen Sabater
GGGeraldine Gueron
Geraldine Gueron
Interferon gamma (IFN-γ) may be potential adjuvant immunotherapy for COVID-19 patients. In this work, we assessed gene expression profiles associated with the IFN-γ pathway in response to SARS-CoV-2 infection. Employing a case-control study from SARS-CoV-2-positive and -negative patients, we identified IFN-γ-associated pathways to be enriched in positive patients. Bioinformatics analyses showed upregulation of MAP2K6, CBL, RUNX3, STAT1, and JAK2 in COVID-19-positive vs. -negative patients. A positive correlation was observed between STAT1/JAK2, which varied alongside the patient’s viral load. Expression of MX1, MX2, ISG15, and OAS1 (four well-known IFN-stimulated genes (ISGs)) displayed upregulation in COVID-19-positive vs. -negative patients. Integrative analyses showcased higher levels of ISGs, which were associated with increased viral load and STAT1/JAK2 expression. Confirmation of ISGs up-regulation was performed in vitro using the A549 lung cell line treated with Poly (I:C), a synthetic analog of viral double-stranded RNA; and in different pulmonary human cell lines and ferret tracheal biopsies infected with SARS-CoV-2. A pre-clinical murine model of Coronavirus infection confirmed findings displaying increased ISGs in the liver and lungs from infected mice. Altogether, these results demonstrate the role of IFN-γ and ISGs in response to SARS-CoV-2 infection, highlighting alternative druggable targets that can boost the host response.

28 November 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
ATAyelén Toro
Ayelén Toro
AAAna Paula Arévalo
Ana Paula Arévalo
MPMarianoel Pereira-Gómez
Marianoel Pereira-Gómez
Agustina Ayelen SabaterAgustina Ayelen Sabater
Agustina Ayelen Sabater
EZEric A. Zizzi
Eric A. Zizzi
GGGeraldine Gueron
Geraldine Gueron
Recent developments have broadened our perception of SARS-CoV-2, indicating its capability to affect the body systemically beyond its initial recognition as a mere respiratory pathogen. However, the pathways of its widespread are not well understood. Employing a dual-modality approach, we integrated findings from a Murine Hepatitis Virus (MHV) infection model with corroborative clinical data to investigate the pervasive reach of Coronaviruses. The novel presence of viral particles within red blood cells (RBCs) was demonstrated via high-resolution transmission electron microscopy, with computational modeling elucidating a potential heme-mediated viral entry mechanism via Spike protein affinity. Our data affirm viral localization in RBCs, suggesting heme moieties as facilitators for cellular invasion. Exacerbation of MHV pathology upon hemin administration, contrasted with chloroquine-mediated amelioration, underscoring a heme-centric pathway in disease progression. These observations extend the paradigm of Coronavirus pathogenicity to include hemoprotein interactions. This study casts new light on the systemic invasion capabilities of Coronaviruses, linking RBC hemoproteins with viral virulence. The modulation of disease severity through heme-interacting agents heralds a promising avenue for COVID-19 therapeutics. Our findings propose a paradigm shift in the treatment approach, leveraging the virus-heme interplay as a strategic hinge for intervention.

Verified
Journal Article
Open access
PDF file
Agustina Ayelen SabaterAgustina Ayelen Sabater
Agustina Ayelen Sabater
PSPablo Sanchis
Pablo Sanchis
RSRocio Alejandra Seniuk
Rocio Alejandra Seniuk
GPGastón Mario Pascual
Gastón Mario Pascual
NANicolas Anselmino
Nicolas Anselmino
GGGeraldine Gueron
Geraldine Gueron
Prostate cancer (PCa) poses a significant global health challenge, particularly due to its progression into aggressive forms like neuroendocrine prostate cancer (NEPC). This study developed and validated a stemness-associated gene signature using advanced machine learning techniques, including Random Forest and Lasso regression, applied to large-scale transcriptomic datasets. The resulting seven-gene signature (KMT5C, DPP4, TYMS, CDC25B, IRF5, MEN1, and DNMT3B) was validated across independent cohorts and patient-derived xenograft (PDX) models. This signature demonstrated strong prognostic value for progression-free, disease-free, relapse-free, metastasis-free, and overall survival. Importantly, the signature not only identified specific NEPC subtypes, such as large-cell neuroendocrine carcinoma, which is associated with very poor outcomes, but also predicted a poor prognosis for PCa cases that exhibit this molecular signature, even when they were not histopathologically classified as NEPC. This dual prognostic and classifier capability makes the seven-gene signature a robust tool for personalized medicine, providing a valuable resource for predicting disease progression and guiding treatment strategies in PCa management.

20 May 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PSPablo Sanchis
Pablo Sanchis
DADiana C. Aguilar-Cortes
Diana C. Aguilar-Cortes
BKBalachander Kannan
Balachander Kannan
RMRafat Malik
Rafat Malik
JMJoaquin Merlo
Joaquin Merlo
Annie Wai Yeeng ChaiAnnie Wai Yeeng Chai
Annie Wai Yeeng Chai
Cancer is a global disease, yet a paradox persists: The most advanced research ecosystems are concentrated in countries with lower disease burden, whereas low- and middle-income countries (LMIC)—carrying 70% of the global cancer burden—face major constraints in research capacity. Closing this gap is essential for equitable progress in cancer prevention, diagnosis, and treatment. Researchers in LMICs are creatively adapting established technologies, research pipelines, and collaborative models from higher-resource settings to local solutions. In this study, 25 American Association for Cancer Research Global Scholar-in-Training Award recipients from LMICs share how cancer research is advancing within resource-limited settings, focused on (i) infrastructure and resources, (ii) training and talent retention, (iii) funding and sustainability, and (iv) cultural and social barriers. We identified shared challenges and cross-cutting solutions, discussed gaps, and suggested steps to further advancing cancer research. We emphasized locally led innovation, strategic partnerships, and community engagement. These perspectives offer a framework for inclusive, synergistic approaches to strengthening cancer research and accelerating impact where it is needed most.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
PSPablo Sanchis
Pablo Sanchis
NANicolas Anselmino
Nicolas Anselmino
RHRosario Lavignolle Heguy
Rosario Lavignolle Heguy
Agustina Ayelen SabaterAgustina Ayelen Sabater
Agustina Ayelen Sabater
ELEstefania Labanca
Estefania Labanca
GGGeraldine Gueron
Geraldine Gueron
Bone hosts the 88% of Prostate Cancer (PCa) metastases and no curative therapy is currently available for this stage. Arrival of PCa cells to the bone homing organ is accompanied by a metabolic adaptation, which may be mediated by bone secreted factors. Herein, we sought to identify key metabolic genes fueling PCa bone metastasis and soluble factors secreted by bone cells leading to the metabolic rewiring of tumoral cells. By an indirect transwell co-culture system of PCa (PC3) and bone progenitor cells (MC3T3, pre-osteoblasts; or Raw264.7, pre-osteoclasts) we analyzed the transcriptome (RNA-seq) of PC3 cells modulated by soluble factors released from bone precursors. GSEA showed a strong activation of lipid metabolism, including PPAR and PI3K-Akt pathways, fat absorption and digestion. We then performed a Principal Component Analysis using transcriptomic data from human PCa and bone metastasis samples (GSE74685), showcasing that those metabolic genes that appeared significantly dysregulated in the co-culture model could accurately cluster samples by their tissue of origin in two defined groups: primary PCa and bone metastasis. This result was confirmed by an unsupervised clustering analysis, highlighting that the transcriptional metabolic profile triggered in the in vitro model has a clinical correlate in human bone metastasis samples. Interestingly, when performing a survival analysis for those genes in the SU2C-PCF dataset, we observed that 4 lipid-associated genes, PPARA, VDR, SLC16A1 and GPX1, correlated with a shorter overall survival time, and appeared as independent risk-predictors of death (HR: 4.96, 2.85, 3.93 and 3.67, respectively; P<0.05). These results prompted us to evaluate the communication axis by which the expression of the lipid transcriptomic signature is regulated in PC3 cells co-cultured with bone progenitor cells. We performed an Ingenuity Pathway Analysis (QIAGEN) showing that the tumoral Protein Kinase A (PKA) appears as a master regulator of this signature. Accordingly, when we treated PC3 cells with the conditioned media (CM) of PC3 grown alone or the co-culture, we observed a decreased ATP content in the latter compared with controls, which is restored upon PKA inhibition, confirming the role of this kinase in the metabolic phenotype of co-cultured cells. Finally, secretome analysis (ESI-MS/MS) of CM from the co-cultures displayed relevant soluble factors secreted by bone progenitors (Col1a1, Fn1) which are directly linked to PKA activity. Overall, we identified an early lipid-related gene signature in PCa cells triggered by the dialogue with bone cells, enough to discriminate metastatic human PCa from primary tumors and critical for PCa survival. This signature may respond to released soluble bone factors through tumoral cell PKA activation. Our findings pinpoint new attractive metabolic druggable targets to halt disease progression. Citation Format: Pablo Sanchis, Nicolas Anselmino, Rosario Lavignolle, Agustina Sabater, Estefania Labanca, Juan Bizzotto, Sofia Lage-Vickers, Gaston Pascual, Rocio Seniuk, Ayelen Toro, Nora Navone, Javier Cotignla, Elba Vazquez, Geraldine Gueron. Early metabolic rewiring of prostate cancer cells triggered by bone progenitors defines survival of metastatic prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2374.